We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Cambrex and Cytori Enter into Collaboration
News

Cambrex and Cytori Enter into Collaboration

Cambrex and Cytori Enter into Collaboration
News

Cambrex and Cytori Enter into Collaboration

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cambrex and Cytori Enter into Collaboration"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cambrex Bio Science Walkersville, Inc., a subsidiary of Cambrex Corporation, and Cytori Therapeutics have announced that they have entered into a strategic marketing agreement to provide adipose-derived stem cell products globally for use in basic and translational bioresearch.

Under the terms of the agreement, Cambrex Bio Science Walkersville, Inc. will manufacture and market products to the research community under the co-exclusive license from Cytori.

In return for the license, Cytori will receive royalties on all cells, media, and related future research products based upon the licensed technology.

Adipose tissue is known to contain a rich population of stem and progenitor cells that have been shown to possess significant regenerative properties in multiple clinical disciplines.

The licensing agreement brings together Cambrex Bio Science Walkersville, Inc. and Cytori.

"Adipose tissue is now a validated source of regenerative cells," said Shawn Cavanagh, Senior Vice President and General Manager, Cambrex Bioproducts business.

"The scientific potential of this population has only begun to be mined, yet already shows promise in clinical case studies."

"We look forward to offering the products to researchers that are conducting basic and preclinical research related to these cells."

"Our relationship with Cambrex ensures that scientists and physicians working on today's most challenging clinical problems including heart and neurological diseases have readily available access to our cell population," said Marc H. Hedrick, M.D., President of Cytori Therapeutics.

"Adipose is a dynamic tissue which, with further study, will help reveal previously hidden biological insights that could be applied toward the discovery of new therapies for a broad range of diseases."

Advertisement